FDA Review Begins for Viatris' Presbyopia Treatment Expansion

Event summary

  • FDA accepted Viatris' sNDA for phentolamine ophthalmic solution 0.75% to treat presbyopia, setting PDUFA goal date for October 17, 2026.
  • The application is supported by positive Phase 3 trial results (VEGA-2 and VEGA-3) showing no treatment-related serious adverse events.
  • Current approval is for pharmacologically-induced mydriasis; sNDA seeks to expand indication to presbyopia.
  • Viatris holds exclusive U.S. commercialization rights through global licensing agreement with Opus Genetics.

The big picture

This sNDA represents Viatris' strategic push into the presbyopia market, a condition affecting 90% of Americans over 45. The company is leveraging its existing phentolamine approval to expand into a massive unmet need, potentially creating a first-mover advantage in the pharmaceutical treatment of age-related vision loss. The acceptance comes as the ophthalmology sector sees increasing innovation in non-surgical solutions for presbyopia.

What we're watching

Regulatory Timeline
Whether the FDA will meet the October 2026 PDUFA goal date for this novel presbyopia treatment indication.
Market Potential
The pace at which Viatris can capture share in the $3 billion+ U.S. presbyopia correction market if approved.
Competitive Dynamics
How this expansion positions Viatris against emerging presbyopia treatments from Allergan and others.

Related topics

Pharmaceuticals